Bioasis Technologies

Bioasis Technologies EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Bioasis Technologies (BIOAF) as of Oct 21, 2026 is -0.05. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -1.47 — a change of -96.55% (higher).

EV/OCF

-0.05

YoY

-96.55%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Bioasis Technologies is 2022 -0.05 . EV/OCF (Enterprise Value to Operating Cash Flow) of Bioasis Technologies was 2021 -1.47 . It decreases by -96.55% higher compared to the previous year.

The Bioasis Technologies EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2015
0.81 CAD
Jan 1, 2016
1.05 CAD
Jan 1, 2017
0.43 CAD
Jan 1, 2018
0.18 CAD
Jan 1, 2019
0.42 CAD
Jan 1, 2020
-0.13 CAD
Jan 1, 2021
-1.47 CAD
Jan 1, 2022
-0.05 CAD
The Bioasis Technologies EV/OCF history
YEAREV/OCFYoY
-0.05-96.55%
-1.47+1,002.28%
-0.13-132.06%
0.42+130.48%
0.18-58.38%
0.43-58.68%
1.05+30.30%
0.81+24.61%
0.65—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Bioasis Technologies is -0.05 in 2022.

EV/OCF (Enterprise Value to Operating Cash Flow) of Bioasis Technologies changed from -1.47 to -0.05, representing a -96.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Bioasis Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bioasis Technologies

All Key Metrics — Bioasis Technologies